REVEAL GENOMICS® HER2DX® Genomic Test to Undergo First Prospective Trial as Part of the DEFINITIVE Project, Funded by the European Commission
The study seeks to secure the prospective validation for endorsement by clinical guidelines and ensure recognition and reimbursement across Europe.
- The study seeks to secure the prospective validation for endorsement by clinical guidelines and ensure recognition and reimbursement across Europe.
- As a collaborating partner in this study, REVEAL GENOMICS® is committed to generating robust evidence designed to influence and evolve standard clinical practices.
- We are immensely grateful to all our partners and the multidisciplinary team participating in this trial.
- The DEFINITIVE trial seeks to assess the clinical efficacy of HER2DX® by comparing the outcomes of patients who undergo the genomic test with those who do not.